We employed the ovarian cancer cell line UWB1.289 that presents a pathogenic frameshift mutation in BRCA1 and an HRD score of 67 as a control to evaluate the drug response of the HRDhigh sarcoma models. This evidence concerns the gene BRCA1 and ovarian cancer.